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Summary: Xenotransplantation may be a solution to overcome the shortage of organs for the 
treatment of patients with organ failure, but it may be associated with the transmission of porcine 
microorganisms and the development of xenozoonoses.  
Whereas most microorganisms may be eliminated by pathogen-free breeding of the donor animals, 
porcine endogenous retroviruses (PERVs) cannot be eliminated, since these are integrated into the 
genomes of all pigs. Human-tropic PERV-A and -B are present in all pigs and are able to infect human 
cells. Infection of ecotropic PERV-C is limited to pig cells. PERVs may adapt to host cells by varying 
the number of LTR-binding transcription factor binding sites. Like all retroviruses, they may induce 
tumors and/or immunodeficiencies.  
To date, all experimental, preclinical, and clinical xenotransplantations using pig cells, tissues, and 
organs have not shown transmission of PERV. Highly sensitive and specific methods have been 
developed to analyze the PERV status of donor pigs and to monitor recipients for PERV infection. 
Strategies have been developed to prevent PERV transmission, including selection of PERV-C-
negative, low-producer pigs, generation of an effective vaccine, selection of effective antiretrovirals, 
and generation of animals transgenic for a PERV-specific short hairpin RNA inhibiting PERV 
expression by RNA interference.  
 
Introduction 
The shortage of allotransplants is the greatest obstacle in organ transplantation. Whereas the number 
of individuals waiting for an allotransplant is steadily increasing, partially due to a longer life 
expectance of the human population, there is not a proportional increase in viable donated organs. As 
of April 2011, more than 111,000 people are on the waiting list for organ transplants in the United 
States (Organ Procurement and Transplantation Network [http://optn.transplant.hrsa.gov/]). Presently, 
a large number of patients needing an organ transplant will die while on the waiting list. Health 
education and organ donation encouragement are suggested as important measures to circumvent 
this organ shortage; however, different strategies have not resulted in an appreciable increase in 
donated organs (5).  
Xenotransplantation, the transplantation of living cells, tissues, and organs between different species 
or ex vivo transspecies exchange of cells, tissues, and organs, is a suggested solution to the allograft 
shortage (51, 97). Clinically, the history of xenotransplantation started in 1964, when Reemtsma 
transplanted a chimpanzee kidney into a human with end-stage renal disease, extending the patient's 
life a record time of 9 months (265). As xenotransplantation improves into a viable alternative to 
allotransplantation, a number of medicinal and biological barriers remain (255). Such hurdles include 
immunological rejection, physiological incompatibilities, and transmission of microorganisms.  
 
Xenotransplantation is also the subject of a broad ethical discussion (4, 311), and clinical 
xenotransplantation should be performed with authorization by regulatory authorities, based on 
comprehensive guidelines, e.g., those of the U.S. Food and Drug Administration (FDA) (102) and the 
European Medicines Agency (EMEA) (99), focusing on safety and benefit-risk ratios. Conditions for 
  
undertaking clinical trials of porcine islet products in type 1 diabetes have been described by the 




The major problem of xenotransplantation is the rejection of porcine cells, tissues, and organs, which 
occurs in several stages: (i) hyperacute rejection (HAR), (ii) acute vascular rejection (AVR), (iii) cellular 
rejection, and (iv) chronic rejection. HAR and AVR are mediated mainly by antibodies against the 
terminal oligosaccharide determinant galactose-alpha-1,3-galactose (Gal) on pig vascular endothelium 
(52). In contrast, human allotransplantation is associated mainly with cellular and chronic rejection.  
HAR is based on preexisting antibodies against Gal-alpha-1,3-Gal residues expressed on pig cells and 
is now being overcome. Early attempts to reduce the amount of these antibodies by adsorption 
strategies failed (156). The most successful approach involves the production of (i) transgenic pigs 
that express human complement regulatory proteins capable of inhibiting the injurious effect of 
antibody-mediated complement activation on the vascularized pig organ (283, 361) and (ii) pigs with a 
knocked-out galactose-alpha-1,3-galactosyltransferase gene locus (GalT-KO pigs) (62, 168, 253).  
 
This genetic knockout prevents expression of Gal-alpha-1,3-Gal residues. When hearts from GalT-KO 
pigs were transplanted heterotopically into baboons by use of an anti-CD154 monoclonal antibody-
based regimen, the elimination of the Gal-alpha-1,3-Gal epitope prevented HAR and extended survival 
of pig hearts in baboons for 2 to 6 months (median, 78 days); the predominant lesion associated with 
xenotransplant failure was a thrombotic microangiopathy, with resulting ischemic injury (167). 
Significant prolongation of life-supporting pig-to-baboon renal xenograft survival, for up to 83 days, 
with normal creatinine levels in baboons, was achieved using GalT-KO donors and a tolerance 
induction approach (353).  
The problem in overcoming AVR is incompletely understood and cannot be controlled yet. However, 
progress is being made on several fronts, including the development of new immunosuppressive 
drugs and further attempts to genetically engineer pigs. Although the strength of cellular rejection in 
xenotransplants remains uncertain, it is expected to be stronger than that observed in allografts. 
Based on the severity of the T-cell-dependent B-lymphocyte response resulting in antibody formation 
and the role of antibodies against the transplant in chronic rejection of an allograft, it can also be 
anticipated that chronic rejection of xenotransplants will be more aggressive than that of 
allotransplants. However, data for this scenario are not available. Overcoming these barriers will 
probably require severe and sustained exposure to immunosuppressive drugs or breakthroughs in the 




Extensive research is needed to determine whether animal organs can replace the physiological 
functions of human organs. Research has been performed in fields such as anatomical design, 
metabolism, hormonal function, blood viscosity, and coagulation (123, 262, 323). Pig-to-primate kidney 
transplants function well on several levels but lack compatibility with respect to erythropoietin (EPO) 
function, since porcine EPO differs to a greater extent from human EPO (123). Human recombinant 
EPO would need to be substituted in the patients. It can be anticipated that pig-to-human transplants 
of hearts, kidneys, and lungs will be physiologically feasible.  
However, this is not the case for whole-organ liver transplants, where differences between many of the 
proteins manufactured in the liver (approximately 2,000) may prohibit adequate function. In addition, 
xenotransplantation of lungs will require more research into their physiology (225). It has become clear 
that coagulation dysfunction between recipient and donor, as well as inflammation, contributes 
significantly to different survival times and to the loss of the xenotransplant (262). The induced 
thrombotic microangiopathy causes ischemic injury to the myocardium during heart transplantations 
and finally results in consumptive coagulopathy (31, 142).  
  
Risks of Infectious Disease 
 
The infectious disease risks of xenotransplants pose a problem for the recipients of organ transplants 
and the public at large. The public health risk represents a major concern, and after it was 
documented that porcine endogenous retroviruses (PERVs) infect human cells in an in vitro coculture 
assay, it was perceived that xenotransplantation might create a new epidemic infectious disease (46, 
66, 333, 334, 340). This perception seemed logical, as it was at that time known for just a few years 
that infection of humans with human immunodeficiency virus (HIV) and the AIDS pandemic were the 
result of a transspecies transmission of a retrovirus, simian immunodeficiency virus (SIV), to humans. 
Thus, the same potential was perceived for PERVs, because PERVs are also retroviruses; however, 
they are not closely related to HIV (see below). A putative spread of infectious diseases via pig-to-
human transplants and the inability to assess the risk led the FDA in 1997 to place a hold on ongoing 
clinical trials involving new drug developments and cellular transplants, such as with porcine islet cells, 
hepatocytes, and others, pending the development and implementation of monitoring strategies (20, 
21). Because PERVs are found in the DNA of all pigs, they cannot be eliminated from all 
xenotransplants. In contrast, most other infectious diseases of pigs can be excluded by appropriate 
breeding and safety measures that produce designated or qualified pathogen-free colonies.  
Meanwhile, there is evidence from a number of case studies that PERV infection in human recipients 
of xenotransplants is nonexistent, although most of the human recipients were exposed to porcine 
tissue for relatively brief periods (for a review, see reference 70). Nevertheless, any clinical trial 
involving a xenotransplantation product has to be addressed adequately regarding the safety concerns 
identified over the years.  
 
Pigs as a source for Xenotransplantation 
 
Despite the genetic differences and evolutionary distance between pigs and nonhuman primates, pigs 
show numerous advantages as donor animals (Table 1). It is still unclear whether the risk of infection 
is higher with the use of pigs than with the use of nonhuman primates. However, due to the genetic 
relatedness of receptors and cell metabolism, it seems much easier for microorganisms, including 
viruses, from a nonhuman primate to infect humans than for microorganisms, including viruses, from 
pigs. An illuminating example is HIV-1, which is the result of a transspecies transmission from closely 
related chimpanzees to humans, using the same viral receptors on immune cells (122).  
Simple screening methods for porcine microorganisms should be developed, e.g., microarrays, which 
have been used already for the screening of other retroviruses (291).  
 
 
Use of transgenic pigs to overcome immunological rejection 
In the last few years, numerous transgenic pigs were generated with the goal of diminishing 
immunological rejection. First of all, HAR may be overcome by two different strategies, i.e., (i) gene 
knockout to remove the terminal carbohydrate epitopes Gal-alpha-1,3-Gal from the surfaces of pig 
cells by inactivation of the corresponding enzyme, Gal-alpha-1,3-galactosyltransferase, which adds 
the terminal Gal residue; and (ii) expression of human complement regulatory proteins on the surfaces 
of pig cells (for a review, see references 161 and 250) (Table 2).  
 
The human complement regulatory proteins prevent complement-assisted destruction of the 
transplant. However, when retroviruses bud from the surfaces of cells from transgenic pigs expressing 
human complement regulator proteins, the viruses acquire numerous cellular proteins, including these 
human complement regulatory proteins. Expression of these proteins on the virus surface will also 
prevent the human immune system from eliminating the virus (235, 260, 316), increasing the risk of 
transmission. 
 
Without the human complement regulator genes on the surface of PERV, anti-Gal-alpha-1,3-Gal 
antibodies prevent virus infection (207, 208). In addition to the complement regulators, genes involved 
in adaptive immune responses and coagulation, e.g., the HLA-E/human beta2-microglobulin (338), the 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (160), the tumor necrosis factor alpha-
  
induced protein 3 (A20) (240), thrombomodulin (251), and human heme oxygenase-1 (hHO-1) (252), 
have also been expressed in transgenic pigs.  
 
Infection barriers 
Bacteria, Fungi, and Parasites 
 
Lists of bacteria, fungi, and parasites able to be transmitted to human recipients and able to induce 
known and unknown zoonoses have been published (70, 109, 237, 286, 329), but the number and 
specification of the microorganisms which should be eliminated necessarily from the donor animal 
because of their putative pathogenic impact are still unclear and may also be dependent on the 
country or continent. In addition, to exclude these microorganisms from pigs generated as source 




As in the case of bacteria and other microorganisms, viruses with zoonotic potential for human 
xenotransplant recipients can be eliminated only when the virus is known and when sensitive detection 
assays are available (Table 3). Most of the viruses listed (70, 286, 329) can be eliminated easily, but 
others can be eliminated only with some restrictions. For example, infectious circoviruses can be 
transmitted from the sow via the placenta and represent a special risk (106, 245, 330), because 
exclusion by Caesarean section is circumvented in this case. Viruses of special risk include 
herpesviruses, which are difficult to detect (40, 41, 330), paramyxoviruses such as Hendra virus (331), 
Nipah virus (43), Menangle virus (27), and Tioman virus (44), as well as PERVs (246), which are 
integrated into the pig genome (see below).  
 
The exclusion of potential zoonotic pathogens from animal herds under qualified pathogen-free 
breeding has been discussed widely (308), and comprehensive guidelines on screening for infectious 
agents, including viruses, have been issued, e.g., by the FDA/U.S. Public Health Service (PHS) (102) 
and the WHO (233); however, these do not contain a comprehensive list of pathogens to be excluded 
from pigs used for xenotransplantation. Viruses with the potential to cross the species barrier, 
including encephalomyocarditis virus (EMCV), hepatitis E virus (HEV), porcine cytomegalovirus 
(PCMV), and porcine gammalymphotropic herpesvirus (PLHV), should be excluded from the herd (2, 
41, 213, 214, 339).  
 
Other viruses to be excluded are swine caliciviruses, including sapoviruses causing gastroenteritis in 
humans (363), swine torque virus (209), and Reston ebolavirus (13). Although the Reston virus—in 
contrast to the other filoviruses, Ebola virus and Marburg virus, both inducing fatal hemorrhagic 
fever—does not induce a disease in humans, its presence in pigs is of concern. All of these viruses 
must be included in the list of microorganisms that need to be tested for in donor pigs.  
Of special interest is the question of whether human viruses can infect and harm the pig 
xenotransplant. Although the risk of infection of the xenotransplant by human viruses may be low 
because of missing receptors and an incompatible cell metabolism, some human viruses, such as 
human cytomegalovirus, human adenovirus, and hepatitis C virus, infect pigs (for a review, see 
references 215 and 216). It remains unclear whether infection with human viruses will harm the 
xenotransplant, whether porcine and human viruses may interact (276), and whether screening for 




Endogenous retroviruses in eukaryotic species are usually the result of a transspecies transmission of 
a retrovirus and its integration into the germ line of the new host (72). The origin of PERVs was most 
likely a murine retrovirus (185). PERVs are present in the genomes of all pigs (182, 246, 248), and 
some are able to infect human cells in vitro (61, 164, 246, 298, 341, 342), therefore representing a 
special risk for xenotransplantation. There are three types of PERVs, namely, PERV-A, PERV-B, and 
PERV-C. PERV-A and PERV-B are present in the genomes of all pig strains, at different copy 
  
numbers, and PERV-C is integrated into the genome in many, but not all, pigs (Fig. 1). Whereas 
PERV-A and PERV-B are polytropic and able to infect human cells and cells of other species, PERV-C 
is ecotropic and restricted to pig cells. Transspecies transmissions of retroviruses have been shown 
for many retroviruses, among them HIV-1 and HIV-2, causing the AIDS pandemic, the most disastrous 
example of a transmission of a zoonotic retrovirus to humans (122). In addition, human T-cell leukemia 
virus type 1 (HTLV-1) and HTLV-2 are other examples of transmission of retroviruses from nonhuman 
primates to humans (335). Transmission of retroviruses closely related to PERV, such as the 
transmission of koala retrovirus (KoRV) from still unknown rodents to koalas, has also been described 
(69, 103, 319, 320). The transmitted retroviruses induce lymphomas (KoRV), leukemias and 
neurodegenerative diseases (HTLV), and/or immunodeficiencies (HIV, HTLV, and KoRV) in the new 
host. The severity of the immunodeficiency depends on the virus load of the virus in the infected host.  
 
Biology of PERVs. 
 
Replication-competent viruses encoded by the PERV sequences are morphological type C 
retroviruses and belong to the genus Gammaretrovirus of the family Retroviridae. Their genome is 
RNA, and the most important viral enzyme is the reverse transcriptase (RT), transcribing the viral RNA 
genome into proviral DNA. Viral particles have a diameter of about 100 nm (Fig. 2). They are 
assembled at and released from the cellular membrane in a budding process and consist of lipid and 
protein derived from host cells. The precursor molecule of all Gag proteins is cleaved by a viral 
protease into p27Gag or capsid protein (CA), which is the main structural protein; into p10Gag, the 
nucleic acid-associated protein; and into the membrane-associated protein MA. The pol gene codes 
for the RT, the integrase (IN), and protease (PR), enzymes required for the transcription of the viral 
RNA into DNA and for integration of the DNA copy into the cellular genome. The main structural 
protein is the CA protein p27Gag. It is smaller than the corresponding protein of murine leukemia virus 
(MuLV), p30Gag (313). The env gene codes for a precursor molecule which is cleaved by a cellular 
furin-like protease into the surface envelope protein gp70 and the transmembrane envelope protein 
p15E. PERV is closely related to feline leukemia virus (FeLV), MuLV, and the baboon endogenous 
retrovirus (BaEV). Antibodies against p27Gag of FeLV and p30Gag of MuLV cross-react with p27Gag 
of PERV and vice versa; however, an antiserum against p24Gag of HIV-1 does not—as expected—
cross-react with p27Gag of PERV (313). Antibodies specific for the transmembrane envelope protein 
p15E of PERV react with p15E of FeLV and KoRV and vice versa (J. Denner et al., unpublished data). 
The life cycle of PERV begins with the infection of the target cell and ends with the release of progeny 
viruses (for details, see Table 4 and Fig. 3).  
The release of PERV particles by normal pig cells, if any, is very low; the virus production by certain 
human cells infected with PERV-A and recombinant PERV-A/C (see below) is much higher and 
increases after adaptation to human cells (82, 128, 341). Using Northern blotting and RT-PCR 
methods, the expression of PERV-specific mRNA was studied in different pig tissues (3). The 
presence of a full-length 8-kb mRNA, coding for Gag and Pol, and of a spliced 3-kb mRNA, coding for 
Env, is the prerequisite for virus production and was seen in PERV-producing cells (154). Expression 
of both mRNA species was also seen in blood lymphocytes, the spleen, the thymus, lymph nodes, and 
lungs. Stimulation of blood lymphocytes with the mitogen phytohemagglutinin (PHA) increases the 
expression of PERV (313, 314, 341, 342).  
 
The amount of released virus depends on the pig strain. Miniature pigs are characterized by very high 
expression, and German landrace pigs are characterized by a low expression profile (87, 313, 314). In 
the heart, only very low expression of PERV was observed (3; I. Bittmann, D. Mihica, R. Plesker, and 
J. Denner, unpublished data). High expression of PERV mRNA was found in melanomas of miniature 
pigs and was higher than that in normal skin (89). However, the expression in the spleens of these 
animals was much higher than that in the melanomas. Low expression of PERV mRNA and absence 
of particle release were observed in pig islet cells from German landrace pigs (144). These results are 
of clinical importance, since islet cells, hearts, and kidneys are first on the list of potential pig 
xenotransplantation products for humans.  
Expression of mRNA was studied in certain specific-pathogen-free (SPF) pigs by use of a sensitive 
RT-PCR method (47). According to the data, PERV-A, PERV-B, and PERV-C were expressed in all 
tissues, with high expression in the kidney, followed by the liver, the lung, and the heart. A low level of 
expression was observed in the pancreas. The differences in expression were due to the 
transcriptional activities of the long terminal repeats (LTR) of PERV acting as a promoter, to the 
  
different numbers of U3 repeat boxes in PERV LTR, and to the presence of transcription factors in the 
cells (82, 281). The expression of PERV-C was much lower than the expression of PERV-A and 
PERV-B. Comparison of the SPF pigs with conventional pigs indicated that PERV mRNA levels were 
in the same range, confirming that the use of SPF pigs would not reduce the risk of PERV 
transmission to human recipients of xenotransplants, as expected. Expression of PERV mRNA was 
detected in pig hearts, kidneys, and spleens by RT-PCR (246).  
In situ hybridization studies of porcine neuronal cells with PERV-A- and PERV-B-specific env probes 
have shown high levels of expression of each variant. By RT-PCR and Northern blot analyses, 
expression of PERV mRNA was shown in the heart, lung, liver, kidney, ear, lymph node, and spleen, 
with the highest level of expression in the lung (59).  
It is important that the methods used in these investigations do not discriminate between spliced and 
unspliced (full-length) mRNAs. Env primers used with this method will detect both types of mRNA. To 
solve this problem, a PCR was developed to discriminate between full-length and spliced mRNAs by 
using primers upstream of the splice donor and downstream of the splice acceptor (154). Only when 
spliced env mRNA is present is the Env protein produced, and virus particles may be released. Gag 
and Pol are translated from the unspliced mRNA. However, expression of mRNA, even spliced mRNA, 
does not automatically mean that virus proteins or particles are produced.  
In the first immunofluorescence analyses using a PERV-specific antiserum against p10Gag, no viral 
proteins were observed in the kidneys, aortas, and hearts of landrace pigs (163). There is evidence 
that in addition to pig tumor cells and immortalized pig cell lines, several normal pig cells release 
PERVs and these viruses are able to infect human cells, e.g., PERVs were produced by mitogen-
stimulated blood cells as measured by an RT assay and an infection assay (313, 314, 341, 342). 
Released and pelleted viruses were studied using RT-PCR and PERV-specific primers. It has been 
shown that all three viruses, PERV-A, PERV-B, and PERV-C, were released from stimulated blood 
cells in the case of a Yucatan miniature pig expressing high levels of PERV (314). Infection of human 
293 kidney cells with blood cell-derived viruses was successful: the transmitted virus was a 
recombinant of PERV-A and PERV-C, with the receptor binding site and host range of PERV-A and 
the LTR of PERV-C (342). The release of virus particles from blood cells was transient, with a peak at 
day 5 (313). Differences in virus production in peripheral blood mononuclear cells (PBMCs) between 
different pigs and pig strains after mitogen stimulation were observed, allowing classification into high- 
and low-producer animals. In contrast to German landrace pigs, Yucatan miniature pigs belong to the 
high producers (87, 313). In Yucatan miniature pigs, expression of the PERV proteins p15E and 
p27Gag was shown in several organs by immunohistochemistry, with the highest expression in the 
spleen, kidneys, and lymph nodes (Bittmann et al., unpublished data) (Fig. 4). The expression at the 
protein level correlated with the expression at the mRNA level. In addition, in the organs with high 
expression, the de novo integration of recombinant PERV-A/C not present in the germ line was 
observed.  
Since mitogen stimulation simulates natural immune responses and stimulation by antigens, the 
elevated expression of PERV in spleen and lymph nodes may indicate ongoing immune responses. 
Recently, significant expression of PERV was reported for commercial swine operations in the United 
States, and an increased incidence of PERV-A/C viremia was described for diseased pigs (242). Since 
these results are very interesting, they need to be confirmed in other laboratories. As outlined below, 
screening large numbers of animals by use of ultrasensitive PCR methods requires a clean PCR suite 
with optimal contamination management guided by good laboratory practice to avoid false-positive 
results.  
Release of PERV-A and PERV-B from primary aorta endothelial cells (PAEC) was observed, and both 
viruses infected human 293 kidney cells. Virus production was shown for PAEC from German, 
Russian, and French landrace pigs as well as from Yucatan miniature pigs, Göttingen miniature pigs 
(196), and NIH miniature swine (261, 290, 347). Since endothelial cells, as part of all solid organ 
transplants, as well as passenger leukocytes in tissue will be transmitted with solid organs, these 
results underline the risk arising from the transplantation of vascularized pig organs. Of interest is the 
question of whether PERV may be released from nonvascularized cellular xenotransplants. Production 
of PERVs able to infect human kidney cells in vitro has been claimed for pig pancreatic islet cells 
xenotransplanted into SCID mice (332). However, we were not able to confirm these results (143). In 
addition, it was demonstrated that the reported infection of human cells in SCID mice was due to 
pseudotyping of PERV genomes with the murine xenotropic endogenous retrovirus MuLV-X and is an 
  
artifact of the murine model (355). Although RT activity was found in serum taken from an hDAF 
transgenic pig, indicating the presence of retroviral particles, these viruses were noninfectious for 
human cells (59). However, it is also possible that the RT activity was derived from enzyme released 




Recombinants between PERV-A and PERV-C naturally occurring in miniature swine have been 
described (14, 89, 198, 236, 343, 347) (Fig. 1). The acquisition of the receptor binding site of PERV-A 
enables the recombinant viruses to infect human cells. In comparison to that of parental PERV-A, the 
titer of recombinant PERV-A/C is much higher, and a critical substitution at position 140, localized 
between the variable regions A and B (VRA and VRB), and another substitution within the proline-rich 
region of the receptor binding domain were identified (128).  
An additional increase in virus titer was observed when a recombinant PERV-A/C derived from pig 
PBMCs was serially passaged on uninfected human 293 kidney cells in vitro in order to simulate the 
situation during xenotransplantation (82, 342). This increase was due to an increase in the length of 
the LTR and a multimerization of the nuclear factor Y (NF-Y) transcription factor binding sites (82). 
Changes in the LTR length were also observed for PERV-A passaged on human 293 cells (82, 280). 
The changes were based on the multimerization of 37- or 39-bp repeats containing NF-Y binding sites. 
It has been shown by luciferase reporter assays that multimerization of NF-Y binding sites in the LTR 
functionally mediates increased transcription rates of PERV (82, 280, 281). Changes in the LTR have 
been reported for other gammaretroviruses, such as the feline and murine leukemia viruses, to be 
associated with increased tumorigenicity (11, 12, 83, 304). These data indicate the possibility that 
PERV can adapt to human cells and subsequently replicate with greater efficiency.  
Two different PERV-A/C were found in miniature pigs with melanomas; however, these proviruses 
were integrated only in the spleen, not in the skin, melanomas, and lymph nodes of the animals (89). 
De novo integrated PERV-A/C not present in the germ line were also found in some organs of 
clinically healthy Yucatan miniature pigs characterized by extremely high expression of PERV-A, 
PERV-B, and PERV-C (Bittmann et al., unpublished data).  
Although PERV-A/C were shown to replicate and integrate de novo in healthy (14, 236, 342, 347) and 
diseased (89) pigs, a first attempt to infect PERV-C-negative pigs in vivo with a cell-free high-titer 
PERV-A/C failed (158). Neither provirus integration in different organs nor antibody production was 
observed in the inoculated animal.  
The risk of such recombinant PERV-A/C generated in pigs and integrated de novo into the genomes of 
somatic cells for xenotransplantation is obvious (71). However, this risk can easily be eliminated by 
using pigs not containing PERV-C in their germ line, thus preventing recombination with PERV-A. 
Another reason not to use PERV-C-containing pigs for breeding is based on the ability of 
gammaretroviruses, including PERV, to infect cells not harboring the specific receptor by receptor-
independent infection (9, 177). In the presence of another retroviral surface envelope protein, e.g., 
from a human endogenous retrovirus (HERV), and its receptor, PERV-C may infect human cells 
despite these cells not expressing a PERV-C-specific receptor. A third reason not to use PERV-C-
containing pigs is the possibility that mutations in the proline-rich domain of the Env protein of PERV-C 
may occur and change the tropism of the virus. Mutations in the C-terminal end of the surface 
envelope protein of PERV-C have been described which finally resulted in binding to and infection of 
human cells (119).  
 
Distribution of PERVs 
 
The prevalence and distribution of replication-competent PERV within different pig subspecies and 
transgenic animals used for xenotransplantation are of particular interest. This knowledge allows 
selection for animals with a low copy number of PERV proviruses. Genomic mapping studies have 
shown that there are between approximately 10 and 100 proviral PERV loci in the genomes of various 
pigs (3, 25, 135, 181). Most of these proviruses are defective, and some animals of a miniature swine 
herd do not release human-tropic PERV (236). In addition, some animals produce PERV-C, which can 
  
recombine with PERV-A and generate a recombinant PERV-A/C (261). Unique full-length proviruses 
have been discovered by screening genomic libraries, and some of them were generated in bacterial 
artificial chromosomes (BACs) and were localized chromosomally (Table 5) (227, 228, 267, 268, 289, 
290).  
 
Three of these PERVs showed productive infection upon transfection into cells in culture, while one 
was disabled by two in-frame stop mutations in pol in an otherwise intact proviral context. Further 
analysis of these clones by performing PCR with primers derived from the flanking genomic 
sequences showed that all proviruses were polymorphic in different individuals and demonstrated 
slight alterations within their coding sequences. As a consequence, the individual proviruses were 
present in some pigs and absent in others, and one provirus present in a defined chromosomal 
position may have had mutations in individual pigs and in different subspecies. Most notably, the 
polymorphisms in another proviral PERV clone that was located in the swine leukocyte antigen region 
on pig chromosome 7 revealed an intact pol open reading frame (ORF) in some other Large White 
pigs (228).  
Two clones derived from a library of the porcine cell line PK15 were also characterized (164), but they 
were not localized chromosomally. It is not clear whether these clones are different from the BAC 
clones or whether the genomic flanking sequences are different due to massive rearrangements 
during passaging of the cells over decades, as PK15 cells are malignant and transformed (95). For 
these six PERV clones, their distribution among individual pigs as well as different breeds, i.e., Large 
White pigs, miniature pigs, Westran pigs, and wild boars, was analyzed (Table 5).  
In addition to the endogenous gammaretroviruses, endogenous betaretroviruses have also been 
detected in the genomes of all pigs (96). These viruses are present in the genomes of all pigs, but they 




Interference studies using appropriate env sequences in pseudotyped viruses revealed that the 
different PERV classes use different receptors, thereby explaining the different cell and species 
tropisms observed in pseudotype assays (318). At the moment, only the receptors for PERV-A, 
HuPAR-1 and HuPAR-2 (human PERV-A receptors 1 and 2), have been identified (101). The natural 
function of the receptors is still unknown; however, since they contain 10 or 11 transmembrane 
domains, a function as a transporter similar to the receptors of many other gammaretroviruses (241) 
can be suggested. The baboon homologue was functional, whereas the mouse homologue was not 
able to support PERV infection due to a point mutation (Leu-109-Pro) in the second extracellular loop 
(204). This agrees with data showing that mouse cells could not be infected in vitro (297, 318, 343), 
and infection experiments using high-titer PERV in vivo were negative (143). Reports claiming 
infection of mice with PERV (48, 64, 332) were based on pseudotyping of PERV with murine 
endogenous retroviruses (199, 355). Mice transgenic for HuPAR-1 were generated, and it was 
reported that they could be infected with PERV in vivo (200).  
Interestingly, in rats, the receptor is functional but normally expressed at a very low level (204) not 
allowing infection with PERV in vitro (81, 297, 343) and in vivo (81, 297). Transfection of rat cells with 
human and rat PAR-1 conferred PERV-A susceptibility (204).  
Although cells from nonhuman primates, including chimpanzees, could be infected with high-titer 
PERV-A/C but not with low-titer PERV (22, 154, 266, 299, 301), virus replication was inefficient (203). 
In rhesus macaques, cynomolgus macaques, and baboons, the main receptor (PAR-1) was found to 
be genetically deficient by a mutation at the same position as that reported for mice (Leu-109-Ser), 
partially explaining the inefficiency of infection. The receptor in African green monkeys does not have 
this mutation, but nevertheless the replication is quite low (203).  
HuPAR-2, the second receptor, also has two regions important for infection. In one region, a single 
amino acid residue determines binding; however, in both regions, multiple residues influence receptor 
function for PERV-A entry (193). Whether cellular entry cofactors play a role, as shown for other 
retroviruses (241), is still unclear. At the viral site in the surface envelope protein gp70, two domains, 
i.e., VRA and VRB, are necessary for infection, and in addition, sequences in the proline-rich region 
are also involved in receptor binding (9).  
  
Methods to detect PERV infections 
 
PERV and PERV infections may be detected directly by showing the presence of the provirus in the 
cells, the expression of viral mRNA or viral proteins, and production of infectious viruses. Indirect 
detection methods measure the immune response of the infected host as a result of productive 
infections (Table 6) (75, 130, 312).  
In order to measure provirus integration, PCR and real-time PCR methods have been developed (8, 
23, 159, 189, 310), as well as Southern blot hybridization methods (3, 61), using PERV-specific 
primers and probes, respectively. In addition, a melting assay for estimation of the copy number of 
PERV in pigs has been developed (349). Chromosomal localization of proviruses as well as 
expression of viral RNA was investigated using fluorescence in situ hybridization (FISH) (267, 268, 
347). Viral RNA, either mRNA in the infected cell or genomic RNA in released virus particles, was 
measured by RT-PCR assays (312).  
Virus protein expression was studied using specific antisera in an immunoperoxidase assay (IPA) 
(302), an immunofluorescence assay (61, 107, 163), and a Western blot assay (158, 202, 312) and by 
immunohistochemistry (Bittmann et al., unpublished data) (Fig. 4). Virus production was analyzed 
using an assay for RT activity, which measures virus particles containing RT, or by titration, measuring 
infectious viruses (297, 298, 313).  
Virus production and morphology were studied by transmission electron microscopy (89, 192, 300) 
(Fig. 2) or by scanning electron microscopy (154, 299) (Fig. 2) to characterize the viral particles. 
Immunogold electron microscopy was used to study the localization of viral proteins in the virus 
particle, using specific antiviral immune sera against the transmembrane envelope protein and Gag 
(107, 258, 302).  
Indirect methods measure either the humoral or cellular immune response of the infected host. 
Although no methods for detection of cellular responses against PERVs have been developed until 
now, numerous methods exist to measure the antibody response (115, 312). First, Western blot 
assays were performed using cross-reacting antisera against gibbon ape leukemia virus (GaLV) or 
FeLV as control sera and recombinant Gag protein or infected cells as antigen. Subsequently, PERV-
specific antisera were developed (70, 312). Using these methods, sera from healthy blood donors, 
patients with clinical xenotransplantations, and butchers were examined (70, 244, 312). Butchers in 
large slaughterhouses were of special interest because of their close blood-blood contact with pigs.  
 
For several retroviruses, including HIV-1, it has been shown that blood-blood contact is the most 
efficient route of transmission. None of the tested persons showed evidence of PERV infection. 
However, 4 xenotransplantation patients and 9 healthy controls (blood donors, butchers, and pregnant 
women) showed an antibody response to p27Gag (244, 312). Since there were no antibodies detected 
against other viral proteins, the antibodies against Gag do not indicate an infection but most likely 
represent cross-reactive antibodies. Such cross-reactive antibodies have been described for other 
retroviruses. For example, cross-reacting antibodies against p24Gag of HIV-1 (279) or against Gag of 
the human endogenous retrovirus HERV-K (80) have been detected in healthy individuals. Their 
origin, however, is still unknown. Therefore, for diagnostic purposes, the presence of antibodies 
specific for at least two viral proteins, one Gag and one Env, should be analyzed.  
Monitoring future xenotransplant recipients could include the methods described above. The presence 
of PERV proviruses or PERV particles, as well as the expression of PERV in infected cells, can be 
analyzed using molecular biological methods. Immunological methods, including screening assays 
such as enzyme-linked immunosorbent assay (ELISA) and confirmatory assays such as Western 
blotting, can be used to search for PERV-specific antibodies (for a review, see reference 75). Since no 
PERV infections have been observed until now, specificity and detection limits cannot be evaluated, 
but experience with other retrovirus infections, including HIV-1 infections, clearly demonstrates that 
retrovirus replication in an infected host is accompanied by antibody production (75). Microchimerism, 
e.g., the presence of pig cells in transplanted individuals, even for more than 8 years, did not induce 
an antibody response against PERV (244).  
Lessons should be learned from the false-positive reports of the detection of a murine virus, xenotropic 
murine leukemia virus-related virus (XMRV), in the human population, underscoring the need for 
accurate and specific testing. XMRV is a murine gammaretrovirus closely related to PERV that was 
reported to be present in human patients with prostate carcinoma and chronic fatigue syndrome (CFS) 
  
and also in a substantial percentage of clinically healthy individuals (for a review, see reference 73). 
XMRV was found in patients with prostate carcinoma and CFS by several laboratories in the United 
States but not by European laboratories. There was no association between XMRV and both 
diseases, and there is clear evidence that this virus was a contamination with mouse DNA carrying 
endogenous retroviruses or DNA from human cells infected with XMRV or a direct contamination with 
XMRV (114, 138, 141, 153, 212, 243, 277, 294, 296). This clearly underscores the requirement for a 
clean environment for conducting PCR assays, with optimal contamination management according to 
good laboratory practice, whenever such sensitive PCR methods are used, and it underlines the 
requirement to use immunological methods, in addition to PCR methods, to measure antibody 
production in the transplant recipient for the detection of PERV infections.  
 
Screening of the donor pig 
 
Since most of the potential porcine zoonotic microorganisms will be eliminated by careful screening 
and qualified pathogen-free breeding (287), only the PERVs represent a risk. To select animals with 
low expression of PERV, sensitive and specific PCR, RT-PCR, and real-time PCR methods have been 
developed. Since pigs lacking PERV-C in the genome should be selected to prevent PERV-A/C 
recombinations (79), several methods have been developed to screen for PERV-C in pigs, including 
PCR, nested PCR, and real-time PCR (159).  
 
Expression of all three PERVs could be measured by real-time PCR using specific primers, and 
animals with very low expression of PERV can be selected accordingly. A comprehensive 
characterization of the donor animals is of great importance and has been performed for some herds, 
e.g., for a designated pathogen-free herd in New Zealand (118). In addition to the herd and the 
individual animal, the final transplant (islet cells, heart, or kidney) should be investigated carefully. In 
addition to PCR and RT-PCR, detection of viral proteins and of the release of infectious particles is 
important for the risk evaluation (also see “Risk assessment”).  
 
PERVs and pig tumors 
 
PERVs were first described for transformed pig kidney cell lines (10, 17, 26, 28, 185, 325, 348); later 
viruses were isolated from lymphoma cells (218, 274, 306, 307) and from radiation-induced leukemia 
cells (112). However, there is no evidence for an oncogenic property of PERV.  
When expression of PERVs in melanomas of selectively bred Munich miniature swine (MMS) Troll 
pigs was studied, an increased expression in the tumors compared with normal skin was found (89). 
This breeding herd of MMS Troll is characterized by a high prevalence of melanomas, which 
histologically resemble various types of cutaneous melanomas in humans. Several genetic factors 
have been defined in studying inheritance of melanomas and melanocytic nevi in MMS Troll (336). 
Both the polytropic viruses PERV-A and PERV-B and the ecotropic virus PERV-C are present in the 
genomes of all melanoma-bearing MMS Troll pigs.  
 
PERV expression was found in cell cultures derived from pulmonary tumor metastases (89). During 
passaging of these cell cultures in vitro, the expression of PERV mRNA and protein increased. RT 
activity was found in the supernatant, and release of virus particles was shown by electron 
microscopy. Although PERV expression was elevated in melanomas and melanoma-derived cell 
cultures, the function of the virus in tumor development is still unclear. At the same time, an increased 
expression of a human endogenous retrovirus, HERV-K, was found in human primary melanomas and 
melanoma cell lines (32, 33, 223). Interestingly, in the pigs suffering from a melanoma, PERV 
expression was much higher in the spleen than in melanoma tissue or other organs. These data 
correlate with the enhanced expression of PERV in mitogen-stimulated lymphocytes (313, 314) and 
suggest that immune stimulation in this organ may also activate PERV expression in vivo (86). In 
addition, in the spleen, but not in the tumor or in the skin, de novo integrated PERV-A/C were found 
(see above).  
Immunosuppressive properties of PERV 
 
Many viruses have developed strategies to suppress the immune system of the infected host. For 
example, herpesviruses carry genes in the genome encoding interleukin-10 (IL-10) and decoy cytokine 
  
receptors preventing the action of the natural cytokine (264). The fact that retroviruses are 
immunosuppressive has been known since the 1960s (36; for a review, see references 65 and 238). 
Recently, KoRV, which is closely related to PERV, was found to spread among the koala population in 
Australia. KoRV is highly immunosuppressive, and KoRV infection is associated with fatal 
opportunistic infections, e.g., by chlamydia (320). By analyzing the mechanism of immunosuppression 
by retroviruses, it was shown that the transmembrane envelope protein (201) and a highly conserved 
so-called immunosuppressive domain (isu domain) in this protein are responsible for the 
immunosuppressive activity. Synthetic peptides corresponding to the isu domain inhibited mitogen-
driven proliferation of PBMCs (45, 271). These peptides also modulated cytokine expression in normal 
PBMCs (125). It was later demonstrated that a peptide corresponding to the isu domain of HIV-1 
behaved similarly (76,–,78, 272), suggesting that all retroviruses use their transmembrane envelope 
protein to inhibit the innate and adaptive immune systems after infection (67). Recently, it was shown 
that a mutation in the isu domain of a murine retrovirus closely related to PERV abrogated the ability of 
this virus to replicate in the immunocompetent host; however, it replicated well in 
immunocompromised mice (282). The virus inhibited the function of NK cells as well as CD8
+
 cells, 
indicating that this retrovirus inhibited the innate and adaptive immunity in order to replicate in the 
infected host. In the case of PERV, it was shown that inactivated purified virus as well as the peptide 
corresponding to the isu domain of PERV inhibited proliferation of PBMCs and induced IL-10 
production in human PBMCs (66, 313; Denner et al., unpublished data).  
 
Absence of PERV transmission in preclinical trials and animal infection experiments. 
 
In contrast to in vitro infection studies, animal models allow one to consider the recipient's innate and 
adaptive immune systems upon infection. They also allow the effects of pharmaceutical 
immunosuppression required in future clinical xenotransplantations to be studied. In contrast to future 
human trials, in which PERV infection can be studied primarily in blood cells that are always 
accessible, the use of animal models also allows for examination of a larger range of tissues and 
organs.  
Despite the knowledge obtained from numerous in vitro infection studies that showed that in addition 
to human cells, a broad range of animal cells can be infected in vitro (Table 7), very few animal 
models have been studied until now (for a review, see reference 79). Three types of experiments were 
performed: (i) inoculation of virus, (ii) inoculation of virus-producing cells, and (iii) transplantation of 
living pig cells or organs. Inoculation of rats with PERV or PERV-producing cells (297) or pig islet cells 
(81) and inoculation of PERV into mink (300) or guinea pigs (297) did not result in infection. 
Interestingly, a transient infection was observed in guinea pigs (7). Reports on PERV infection of SCID 
mice (64, 332) and athymic mice (48) represented an artifact of the mouse model: PERV infection of 
murine cells was the result of pseudotyping with endogenous murine retroviruses (199, 355). These 
data closely correlate with the absence of a functional PERV receptor on mouse cells (101) and the 
absence of infection in other mouse models (143, 165).  
Since only short-term survival and function of the xenotransplant have been achieved, no animals with 
long-term functioning xenotransplants can be studied. From this point of view, an unequivocal 
conclusion about PERV transmission might not be possible. On the other hand, the transplant may 
release viral DNA during a rejection process; however, this will not infect the recipient. Last but not 
least, the pig-to-nonhuman-primate transplant models to study cross-species PERV transmission have 
several limitations, including differences in viral receptors.  
As expected, nonhuman primates are of major interest as an animal model for human disease due to 
the genetic relationship to humans. Immunosuppressed recipients of pig-to-baboon aortic endothelial 
cell transplants were found—based on PCR—not to be infected with PERV (197). Similar negative 
results, also obtained using PCR methods, were reported for immunosuppressed baboons and 
cynomolgus monkeys undergoing solid organ transplantation (187, 295) and for a triple-species 
xenotransplantation model (344). Numerous other pig-to-nonhuman-primate transplantations have 
been performed, and no transmission of PERV was observed (Table 8). In addition, in heterotopic 
thoracic pig-to-baboon cardiac xenotransplantation (15), no PERV transmission was observed using a 
Western blot assay to detect PERV-specific antibodies (Denner et al., unpublished data).  
Negative results were also reported for various nonhuman primate species who received high doses of 
a PERV-A/C in combination with a triple immunosuppressive treatment (299, 301). In these 
  
experiments, baboons, pig-tailed monkeys, and rhesus macaques were inoculated with viral 
supernatants from cells producing a PERV-A/C characterized by a long LTR and a high titer. The 
animals were treated daily with three different conventional xenobiotic immunosuppressive drugs at 
pharmacologically active dose levels, namely, the calcineurin inhibitor cyclosporine, the inhibitor of 
mTOR (mammalian target of rapamycin) everolimus (RAD), and methylprednisolone. After more than 
300 days of observation, neither provirus integration in different organs nor antibody production was 
observed in these animals (301).  
Whereas most of the preclinical xenotransplantation studies were retrospective investigations, in the 
first prospective pig-to-nonhuman-primate islet xenotransplantations, the animals were treated with 
encapsulated pig islet cells and analyzed for transmission of potentially zoonotic porcine viruses, 
including PERV, porcine cytomegalovirus (PCMV), porcine lymphotropic herpesvirus (PLHV), and 
porcine circovirus (PCV), using both molecular diagnostic—PCR and RT-PCR—and serologic 
methods. There was no evidence for transmission of any of these pig viruses into the primate 
recipients (116).  
However, since there is a mutation in the PERV receptor in some nonhuman primates (see above), 
significantly reducing the efficiency of infection, the predictive value of this model system—at least 
concerning retrovirus safety—remains unclear.  
 
Absence of PERV transmission in first clinical trials 
 
At present, more than 200 individuals have undergone xenotransplantations of pig cells or tissues, 
including ex vivo perfusion of pig organs or pig cell-based bioreactors (Table 9) (for an extended 
review, see reference 79). No evidence for virus transmission was obtained; also, neither antibodies 
against PERV nor provirus integration in blood cells of the patients was observed. In one study, 
persistent microchimerism was observed in 23 patients, for up to 8.5 years after treatment, without 
PERV transmission (244). In very rare cases, antibodies binding to p27Gag, the main structural 
protein of PERV, were found in Western blot analyses (68, 237, 306). Since no antibodies against 
other viral proteins were detected, an infection was excluded and cross-reactive antibodies were 
considered the reason for the Gag reactivity (see above).  
In another study, 24 patients received porcine fetal neuronal cells for treatment of Parkinson's disease, 
Huntington's disease, and epilepsy. No evidence of PERV provirus integration in the DNA from 
PBMCs of all neuronal transplant recipients was found (92, 105, 284). No tests for antibodies against 
PERV were performed. In addition, no PERV particles were released from cultured fetal porcine 
neuronal cultures, and there was no transfer of PERV from fetal pig neuronal cells to human cells in 
vitro.  
Among the numerous pig cell xenotransplantations and ex vivo perfusions using pig organs that have 
been performed worldwide, bioartificial liver support systems using pig hepatocytes in bioreactors 
have been studied several times (1, 90, 91, 113, 145, 166, 221, 278, 351). In all systems, no 
transmission of PERVs was detected.  
Transmission of PERV was also studied in patients who received unheated porcine clotting factor VIII 
(132, 317). Porcine factor VIII has been used to treat severe bleeding episodes in patients with 
hemophilia who have antibodies against human clotting factors. Viral RNA and RT activity were found 
in the preparations. These findings may indicate either the presence of viral particles in the preparation 
or the presence of viral mRNA and RT molecules released from disrupted cells. If there were virus 
particles, it remains unclear (but seems to be unlikely) whether these particles were still infectious. No 
antibodies against PERV were found in 88 recipients, suggesting that the risk of PERV transmission 
was extremely low.  
There was no evidence of infection with PERV or other porcine microorganisms in recipients of pig 
islet transplants for the treatment of diabetes (98, 117, 324).  
Some studies were performed without analysis of PERV transmission, e.g., in extracorporeal 
connection of pig kidneys to dialysis patients (29). In addition, at least two pig organs (heart and liver) 
were transplanted and rejected, as expected, 24 and 34 h afterwards (60, 190).  
  
Retrotransposition of PERVs 
 
Since it is difficult to exclude all PERV sequences from the pig genome, the question is whether 
truncated PERVs pose an additional risk in terms of retrotransposition, as was shown for another 
gammaretrovirus and close relative of PERV, i.e., Moloney murine leukemia virus (MoMuLV) (129, 
321). The frequencies for retrotransposition were up to 1.2 × 10
−5
 and 8 × 10
−5
 per cell division for 
PERV and MoMuLV, respectively. The variation in frequency between these two gammaretroviruses is 
probably a result of different RT and promoter activities (152). Quantitative RT-PCR analyses based 
on vesicular stomatitis virus glycoprotein G (VSV-G)-pseudotyped PERV and MoMuLV particles 
revealed the same amount of viral RNA copies per transfection.  
However, C-type RT assay analyses based on the corresponding supernatants revealed an almost 10-
fold higher RT activity in the case of MoMuLV. In contrast, reporter gene assays where the luciferase 
gene was regulated by either the PERV or MoMuLV LTR revealed a 3 to 4 times higher promoter 
activity for PERV-B (33) in HeLa cells. Taken together, these results correlate closely with the 
difference in retrotransposition frequency between these two retroviruses. The approximately 10-fold 
stronger RT activity of MoMuLV is counteracted by a 4-fold higher promoter activity of PERV, leading 
to a retrotransposition frequency that is up to 7-fold higher for MoMuLV (152).  
The frequency of MoMuLV transposition correlates with published retrotransposition values (321, 322). 
Electron microscopy to identify extracellular particles, as was done for MoMuLV (321, 322), was not 
performed because immunofluorescence using anti-PERV p10Gag antisera (163) showed no positive 
staining. In addition, no RT activity was detectable in the supernatant of cells transfected with the 
PERV provirus used (R. R. Tönjes et al., unpublished data).  
Cellular restriction factors interfering with PERV.Viruses depend strongly on a number of factors 
provided by their host cell due to their limited genetic coding capacity (337). On the other hand, the 
permissiveness of a host cell is determined by the presence or absence of restriction factors that 
evolved during host-virus coevolution (120, 121, 126, 127, 345). In the last few years, several 
restriction factors were characterized as being of particular importance for the replication of 
retroviruses: TRIM5α, which disrupts the viral capsid (CA) after cell entry; TRIM28, which blocks viral 
transcription; ZAP (zinc finger antiviral protein), which directs degradation of viral RNAs; tetherin, 
which traps virions on the surfaces of infected cells; and APOBEC (apolipoprotein B mRNA-editing 
catalytic polypeptides), which are cytidine deaminases that disrupt viral DNA during synthesis (Table 4 
and Fig. 5) (120, 121, 211, 345). Antiviral restriction systems are being studied with the prospect of 
developing therapeutic agents to regulate the expression of these factors and to enhance antiviral 
activities.  
PERV-A and PERV-A/C are insensitive to restriction by TRIM5α molecules in permissive feline 
Crandall-Reese feline kidney (CRFK) cells expressing TRIM5α proteins from humans, African green 
monkeys, rhesus macaques, squirrel monkeys, rabbits, or cattle (346). However, overexpression of 
either human or porcine tetherin in pig cells significantly reduced PERV production (205).  
The mammalian APOBEC3 (A3) genes are part of the AID/APOBEC gene family, including AID, 
APOBEC1 (A1), APOBEC2 (A2), and APOBEC4 (A4). The family members share structural and 
functional domains of zinc-dependent deaminases (reviewed in reference 49). APOBEC proteins 
deaminate cytidine residues in single-stranded RNA and DNA molecules that are recognized by 
currently unknown mechanisms. Proteins of the A3 group contain one or two zinc (Z)-coordinating 
domains and can be classified according to the presence/absence of a Z1, Z2, or Z3 motif (176, 222). 
In humans, the A3 locus contains seven A3 genes; in rodents, there is one, in pigs two, in horses six, 
and in cats four A3 genes (24, 147, 175, 222, 234, 365), suggesting an amplification during evolution. 
HIV-1 mutants lacking the vif gene can package APOBEC3G (A3G) into virus particles. Incorporated 
A3G specifically deaminates cytidine residues to uracil in growing single-stranded DNA during reverse 
transcription, leading to HIV genome degradation and/or hypermutation (19, 126, 178, 191, 195, 362). 
More recent studies indicated that deaminase-independent mechanisms might also be involved in the 
antiviral activity of A3 (18, 139, 140, 146, 206, 224).  
The mechanism for how retroviruses counteract or escape the A3s from their own host species is 
important for understanding virus tropism and host-virus coevolution (270). In the case of HIV-1, the 
amount of cellular A3G in cells infected with wild-type HIV-1 is dramatically reduced by a Vif-
dependent degradation process via the ubiquitination-proteasome pathway (195, 292, 359, 360). In 
contrast to the well-characterized A3-Vif interaction, little is known about A3-neutralizing strategies 
  
used by retroviruses that do not encode a Vif protein.  
 
Gammaretroviruses such as MuLV or FeLV and PERV appear not to express accessory proteins with 
a function similar to that of the lentiviral Vif protein or the foamy viral protein Bet (186, 222, 249, 273, 
293), both of which inhibit the incorporation of A3 proteins into virions. Despite many studies, the 
debate on the mechanism of resistance of MuLVs to murine A3 (muA3) has not come up with a 
generally convincing model (19, 30, 148, 162, 174, 194). However, recent data clearly showed that 
muA3 is an important in vivo restriction factor of the Friend virus complex and the MoMuLV (188, 275, 
315) that was used as an internal control. Initial studies showed that porcine A3Z2-Z3 (poA3Z2-Z3) 
strongly inhibits HIV-1 and weakly restricts MuLV (149).  
 
Furthermore, it was reported that overexpressed poA3Z2-Z3 did not significantly interfere with PERV 
transmission, and it was concluded that PERV was resistant to its species-specific A3 protein (150). 
Subsequently, the chromosomal porcine A3 locus for poA3Z2 and poA3Z3 was reanalyzed (93, 94). 
Data showed that pigs express four different A3 mRNAs, encoding poA3Z2 and poA3Z3 and, by 
readthrough transcription and alternative splicing, poA3Z2-Z3 and poA3Z2-Z3 splice variant A (SVA). 
It was found that PERV was significantly inhibited by various porcine A3s in single-round as well as 
spreading virus assays. PERV inhibition strongly correlated with a specific cytidine deamination in viral 
genomes for the trinucleotides 5′TGC (edited nucleotide is underlined), for poA3Z2 as well as poA3Z2-
Z3, and 5′CAC, for A3Z3 (93, 94, 179). These results strongly implicate that human and porcine A3s 
can inhibit PERV replication in vivo, thereby reducing the risk of potential infection of human cells by 




PERV does not give any indications of pathology in either its natural host in vivo, infected cells of 
either animal or human lineage in vitro, or recipients of PERV inoculations or preclinical or clinical 
xenotransplantation products in vivo. To date, there has been no indication of infections in small 
animals or nonhuman primates, and hence the effect of PERV in vivo cannot be determined. In 
general, as a retrovirus, PERV might be able to transform infected cells by insertional mutagenesis, as 
demonstrated extensively for MuLV (184). In addition, immunosuppressive properties of PERV have 
been shown (66, 313). However, another important but least assessable risk is posed by the possible 
recombination of PERV with endogenous or exogenous human pathogens, giving rise to absolutely 
new and unexpected viruses (303). Putative recombination with HERVs does not pose a serious risk 
due to the absence of infectious sequences, as in the case of HERV-K (326, 327), or the presence of 
heavily deleted gammaretrovirus-like sequences, as in the case of HERV-R (5). There is no evidence 
for such recombinations and for copacking of sequences from PERV and HERV (305; Denner et al., 
unpublished data).  
PERV has the capacity to pseudotype MuLV particles (318). Other gammaretroviruses have not been 
investigated for this effect, as these do not pose a risk to humans (53). However, risks could evolve for 
xenotransplant patients from gene therapy trials based on MuLV vectors and xenotransplanted pig 
cells.  
To assess the risks of infection and recombination, it is essential to know the exact number and 
location of all replication-competent PERVs. Part of this information was obtained for some pig strains 
(61, 135, 226, 228). However, the elimination of replication-competent PERV proviruses would reduce 
only the release of infectious particles and the probability of recombination between PERV-A and 
PERV-C. It would reduce the risk of malignant transformation and immunosuppression only partially, 
since transposition of deleted proviruses can still induce insertional mutagenesis and the 
immunosuppressive transmembrane protein can be expressed in the absence of other viral genes. In 
addition, non-replication-competent PERVs can recombine or complement each other to produce 
infectious particles.  
Although it is well known that retroviruses induce tumors, leukemias, and/or immunodeficiencies, it is 
difficult to evaluate the risk posed by PERVs. The absence of an in vivo model of PERV infection in 
small animals or nonhuman primates requires insight into the pathology induced by related 
retroviruses. MuLV, FeLV, and KoRV are closely related to PERV. All three gammaretroviruses induce 
leukemias/lymphomas and/or immunodeficiencies. Similar to the situation with HIV-1 infection, 
opportunistic infections develop on the basis of the immunodeficiency. Sixty percent of FeLV-infected 
  
cats die from opportunistic infections, whereas only 5 to 10% develop leukemias/lymphomas. Many 
koalas infected with KoRV suffer from chlamydial infection (319), an opportunistic infection on the 
background of a severe immunodeficiency that is also common in cats infected with feline 
immunodeficiency virus (FIV) (232).  
Inbred miniature swine actually harbor full-length retroviruses (108). However, some animals of the 
strains characterized by the haplotype d/d obviously produced only virions of the ecotropic class 
PERV-C and none of the human-tropic class PERV-A or PERV-B (226, 227, 236). Although ecotropic 
PERV-C infects only pig cells, not human cells, PERV-C might recombine with PERV-A, thus 
transferring genes or parts of them to the human-tropic viruses and therefore posing some risk in the 
course of xenotransplantation.  
Risk assessment is based on studies of the number of PERV copies in the genome and on studies of 
the expression of these proviruses at the levels of RNA and protein. The detection of spliced RNA 
encoding Env is important (154), but most important is the ability to release infectious virus particles 
which may be measured in infection assays. As we demonstrated, mitogen stimulation of immune cells 
increases the release of virus (313, 314). In addition, it should be considered that recombination and 
complementation may lead to virus release from cells previously unable to release virus.  
In conclusion, the virological barriers to xenotransplantation are not as serious as initially perceived 
(110). The number of human-tropic replication-competent proviruses is limited, and the selection of 
PERV-C-free pigs seems possible, reducing the risk of recombination. In addition, recombination 
events with human endogenous retroviruses appear unlikely. As shown below, numerous strategies 
have been developed, including the use of antiretroviral agents, vaccines based on neutralizing 
antibodies, and transgenic pigs with downregulated PERV expression (by RNA interference). Since 
xenotransplantation recipients must be monitored closely for transplant rejection on a routine basis, it 




At present, it is possible that a still unknown microorganism is transmitted from pigs to human 
xenotransplant recipients or from other animals via pigs to humans. Nevertheless, the probability is 
extremely low, assuming that such transmission would have been observed much earlier due to the 
close contact between pigs and humans over a long time. Thanks to improvements in virus 
diagnostics, new, previously unknown viruses have been described for pigs, but most of them are 
nonpathogenic. Some examples are new paramyxoviruses (27), tiomanviruses (44), and kobuviruses 
(354, 358). It is almost impossible to develop systematic strategies to detect such unknown viruses 





General Strategies to overcome Infection Barriers 
Selection of PERV-C-Free Low-Producer Animals 
 
 
At present, the main tool to prevent transmission of porcine microorganisms, including PERV, is the 
selection of the donor animals. As shown above, this includes the absence of PERV-C proviruses and 
low expression of PERV-A and PERV-C. Virus expression can be measured using different methods. 
RT-PCR and real-time RT-PCR allow measurement of expression at the RNA level, and viral proteins 
can be analyzed by immunofluorescence, immunohistochemistry, or Western blot analyses of pig 
tissues. To discriminate between pigs with low and high expression of PERV, a special assay was 
developed based on the measurement of PERV expression after mitogen stimulation of PBMCs (313, 
314). In addition, since recombinants between PERV-A and PERV-C have been described which are 
characterized by high replication titers (for a review, see reference 71), pigs lacking PERV-C in their 
genome should be selected to prevent such recombinations. For this purpose, new methods have 
been developed to screen for PERV-C in pigs, including PCR, nested PCR, and real-time PCR (159).  
 
Vaccination against PERVs 
 
Vaccination of human recipients may be another strategy to prevent PERV transmission, hopefully 
only a theoretical one. Although successful vaccination against HIV-1 and HIV-2 failed (for a review, 
see reference 74), effective vaccines exist against gammaretroviruses such as MuLV and FeLV (137, 
180, 328). The scientific basis of the difference in efficacy is still unknown. When goats, rats, and mice 
were immunized with the transmembrane envelope protein p15E of PERV, binding and neutralizing 
antibodies were induced. These antibodies recognized two epitopes, one in the fusion peptide-
proximal region (FPPR) of the transmembrane envelope protein and the other in the membrane-
proximal external region (MPER) (104, 157). Interestingly, the epitopes in the MPER of the 
transmembrane envelope protein of PERV were localized at the same position as the epitopes of 
antibodies broadly neutralizing HIV-1, originally isolated from HIV-1-infected individuals.  
Since PERV does not infect small animals and nonhuman primates, the efficacy of neutralizing 
antibodies cannot be studied in an animal model. Therefore, infections with related 
gammaretroviruses, e.g., infection of cats with FeLV, have been used. Immunizing rats and goats with 
the transmembrane envelope protein of FeLV resulted in binding and neutralizing antibodies 
recognizing similar epitopes to those after immunization with the transmembrane envelope protein of 
PERV (171). Similar neutralizing antibodies were also induced in cats (173), and after challenging 
these animals with infectious FeLV, 50% of the animals were protected from antigenemia (172). 
Immunization with both the transmembrane and surface envelope proteins resulted in greater immune 
responses (170) and 100% protection (S. Langhammer and J. Denner, unpublished data).  
 
Transgenic Pigs with PERV Expression Inhibited by RNA Interference 
 
RNA interference is a technology inhibiting expression of genes by the action of gene-specific small 
interfering RNAs (siRNAs). Efficient siRNAs corresponding to highly conserved regions in the pol gene 
of the PERV genome were selected and were able to inhibit expression of all PERV subtypes in 
PERV-infected human cells as well as in primary pig cells (155). In addition, a lentiviral vector 
expressing a corresponding short hairpin RNA (shRNA) was used; transfecting pig fibroblasts with this 
construct also resulted in downregulation of PERV expression (86). Using this construct and a control 
construct not containing the PERV-specific shRNA, transgenic pigs were produced by somatic nuclear 
transfer cloning (88).  
 
The integrated transgene was found integrated in the piglets, the shRNA was found expressed in all 
tissues investigated, and PERV expression was significantly inhibited compared with that in control 
animals (88). Similar results were obtained by others (263). Whereas expression of the shRNA was 
studied previously by an in-solution Northern hybridization analysis (86), meanwhile a real-time RT-
PCR was developed to measure expression of the small interfering RNA (M. Semaan, D. Kaulitz, and 
J. Denner, unpublished data). Although differences in the level of PERV expression were observed in 
various tissues, as measured by duplex real-time RT-PCR, the expression of PERV was reduced in all 
organs compared with the expression of PERV in animals carrying a control vector or in comparison to 
  
nontransgenic pigs over a period of more than 3 years (86; M. Semaan, D. Kaulitz, B. Petersen, W. A. 
Kues, H. Niemann, and J. Denner, unpublished data). At present, the effects of multiple PERV-specific 
shRNAs on PERV expression are under investigation. This strategy may lead to animals compatible 
with a safer donor status (less expression of PERV RNA and protein and lower probability of releasing 
infectious virus particles) of a xenotransplantation product concerning PERV transmission.  
Antiretrovirals and PERV Knockout AnimalsSeveral antiretroviral drugs which inhibit replication of HIV-
1 and other retroviruses have been tested against PERV, and the RT inhibitors zidovudine (AZT; also 
known as azidothymidine) and dideoxyinosine (ddI) inhibit PERV replication (257, 259, 302). However, 
RT inhibitors are expected to induce resistant virus strains shortly after the beginning of treatment, as 
shown for HIV-1 in treated individuals.  
All of the strategies listed here are at the investigational level, and their impact on the virus safety of 
xenotransplantation is still unclear. At present, the generation of PERV knockout animals appears to 
be unlikely due to the large number of proviruses, but novel technologies such as the application of 
zinc finger nucleases for the generation of genetically modified animals may generate pigs without 
expression of functional PERV.  
 
Outlook 
The efficacy and safety of xenotransplantation will be shown—according to the proverb “the proof of 
the pudding is in the eating”—in the first clinical trials. The ongoing study of pig islet transplantation to 
diabetic individuals in New Zealand, the first clinical study officially approved by a governmental 
regulatory authority, in 2009, will be one of the first steps on the way to the clinical application of 
xenotransplantation (O. Garkavenko, S. Wynyard, D. Nathu, J. Denner, and R. Elliott, submitted for 
publication).  
This way starts with pig islet transplantation because pig-derived insulin has been used for decades 
for the treatment of diabetes, because in the case of failure the insulin treatment can be continued, 
and because pig islet transplantation has been shown to have the best efficacy thus far in a pig-to-
nonhuman-primate model (287). In analyzing the costs of the treatment of diabetes nowadays, the 
costs for insulin form a very low contribution; most expenses are generated by secondary health 
complications such as amputation, heart and kidney diseases, and blindness.  
 
A total of $174 billion was the total cost for the treatment of diagnosed diabetes in the United States in 
2007, including $116 billion for direct medical costs and $58 billion for indirect costs (disability, work 
loss, and premature mortality). A total of 25.8 million children and adults in the United States, or 8.3% 
of the population, have diabetes. The number of people around the world suffering from diabetes 
increased from 153 million in the year 1980 to 347 million in the year 2008 (63), and it will affect 380 
million people in 2025 (136). A health-economic evaluation suggested that porcine islet cell 
xenotransplantation may prove to be a cost-effective and possibly cost-saving procedure for type 1 
diabetes compared to standard management (16). Pig heart and kidney transplantation may follow, 
using the experience obtained during the first islet cell trials. Immunological, microbiological, and 
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Tables and Figures 
 
 
Table1 Advantages and disadvantages of different animal sources for xenotransplantation 
 
a
 Galactosyl-alpha-1,3-galactosyl epitopes, the main reason for hyperacute rejection (HAR). 
b































 The presence of chromosomally assigned PERVs was tested in six different, geographically separate 
subspecies of Sus scrofa. d/d minipigs (column 7) are genetically related to 
Yucatan minipigs (column 6) but exhibit a defined swine leukocyte antigen haplotype and have been 
described as nontransmitters of PERV. Westran pigs (column 3) are bred in 
Australia. The locations of functional proviruses are indicated in bold. ND, not determined. 
b
 Data are from the work of Rogel-Gaillard et al. (267, 268). 
c
 Data are from the work of Niebert et al. (227). 
d
 Data are from the work of Lee et al. (181). 
e
 Data are from the work of Jung et al. (151). 
  





















 Adapted from reference 79 with permission of Wiley-Blackwell. 
b
 Abbreviations: C1inh, complement C1 inhibitor; CsA, cyclosporine; CyP, cyclophosphamide; EC, 
endothelial cells; FTBI, fractionated total body irradiation; hDAF, human decayaccelerating 
factor; MPA, mycophenolic acid; PAEC, primary aortic endothelial cells; Ster, steroids; STZ, 



























































































































































































































Figure 1 Structure of proviral PERV. (A) Genes and open reading frames are shown as open boxes. 
cap, transcriptional start site; PBS, primer binding site; SD, splice donor; SA, splice acceptor; SU/TM, 
surface/transmembrane envelope protein cleavage site in Env; PPT, polypurine tract, poly(A) addition 
site; LTR, long terminal repeat; gag, group-specific antigen gene; ppro/pol, protease/polymerase gene; 
env, envelope protein gene. (B) Schematic presentation of the subtypes of PERV and the 
recombination events and increase in the length of the LTR during passaging on human cells. Boxes 






Figure 2 PERVs produced by infected human cells as shown by transmission (A) and scanning (B) 




 See Fig. 3 and 5 and the text for references. 
  
Figure 3 Schematic presentation of the life cycle of PERVs.  







Figure 4 Immunohistochemical evidence for the expression of PERV in the white pulp of the spleen of 
a Yucatan miniature swine. The tissue was stained with an antibody specific for the transmembrane 
envelope protein of PERV. 
The immunohistochemical reaction was visualized using the avidin-biotin complex (ABC) method, 
using aminoethylcarbazole (AEC) as the chromogen. (Courtesy of Joachim Denner and Iris Bittmann, 






Figure 5 Interference of different cellular restriction factors with replication of PERVs. For further 
details, see the text and Table 4. 
 
 
